FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
+54.64%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$5.49B
AUM Growth
+$5.49B
(+52%)
Cap. Flow
+$398M
Cap. Flow
% of AUM
7.25%
Top 10 Holdings %
Top 10 Hldgs %
99.42%
Holding
11
New
3
Increased
–
Reduced
2
Closed
–
Top Buys
| 1 |
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
|
$498M |
| 2 |
Foghorn Therapeutics
FHTX
|
$257M |
| 3 |
CDAK
Codiak BioSciences, Inc. Common Stock
CDAK
|
$84.2M |
Top Sells
| 1 |
Denali Therapeutics
DNLI
|
$272M |
| 2 |
Seres Therapeutics
MCRB
|
$169M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $3.23B | 58.71% | 30,871,524 | – | – |
|
|
SGTX
2
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $498M | 9.07% | +10,370,369 | New | +$498M |
|
|
3
Seres Therapeutics
MCRB
$166M
| $360M | 6.54% | 14,673,973 -6,897,791 | -32% | -$169M |
|
|
RUBY
4
DELISTED
Rubius Therapeutics, Inc
RUBY
| $291M | 5.29% | 38,296,526 | – | – |
|
|
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $277M | 5.04% | 22,900,069 | – | – |
|
|
6
Foghorn Therapeutics
FHTX
$286M
| $257M | 4.68% | +12,674,120 | New | +$257M |
|
|
7
Denali Therapeutics
DNLI
$2.23B
| $229M | 4.16% | 2,730,263 -3,250,000 | -54% | -$272M |
|
|
KLDO
8
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $176M | 3.21% | 19,360,710 | – | – |
|
|
CDAK
9
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $84.2M | 1.53% | +2,607,303 | New | +$84.2M |
|
|
AXLA
10
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $65.1M | 1.19% | 12,548,414 | – | – |
|
|
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $31.9M | 0.58% | 2,938,494 | – | – |
|